厚生労働科学研究費補助金

医療機器開発推進研究事業

テロメラーゼ依存性蛍光発現ナノバイオ・ウイルス製剤を標識薬剤とする高感度リアルタイム微小癌転移イメージングシステムの開発

（H21-ﾅﾉ-一般-008）

平成22年度　総括研究報告書

研究代表者　**藤原　俊義**

平成23（2011）年　5月

目　　次

厚生労働科学研究費補助金（医療機器開発推進研究事業）
総括研究報告書

テロメラーゼ依存性蛍光発現ナノバイオ・ウイルス製剤を標識薬剤とする高感度リアルタイム微小癌転移イメージングシステムの開発

研究代表者　藤原　俊義

岡山大学大学院医歯薬学総合研究科・消化器外科学・教授

【研究要旨】

天然に存在する生物由来の蛍光タンパク質は、至適な波長の励起光を吸収することにより強い蛍光を発し、導入した細胞を生きたままの状態で可視化することができる。Green Fluorescent Protein（GFP）をはじめとする蛍光タンパク質を用いた分子イメージングは、最先端の生命科学の研究や技術開発には広範囲に利用されているが、医療への応用は未だ研究段階であり、実際にヒトに臨床応用された事例はない。平成17-19年度の厚生労働科学研究費にて、標識薬剤としてテロメラーゼ活性依存性に癌細胞で選択的に増殖してGFP遺伝子を発現するウイルス製剤TelomeScan（開発コード：OBP-401）を作成し、携帯用接触プローブ型蛍光検出装置の有用性を明らかにしてきた。本研究では、新たに鏡視下手術用の高感度蛍光感知機能を付与したビデオスコープを試作し、大動物でその操作性と有用性を評価することで、最近の腹腔鏡・胸腔鏡手術の普及に対応した、より実践的な低侵襲治療の確立を目指す。本年度は、GFP遺伝子を導入したヒト癌細胞をペレット状にして大動物に投与し、初年度に試作した高感度蛍光検出ビデオスコープで緑色蛍光が明瞭に観察可能であることを明らかにした。また、組織透過性の高い近赤外Katushka蛍光遺伝子を挿入した非増殖型アデノウイルスベクター（Ad-Katushka）を作成した。

A．研究目的

天然に存在する生物由来の蛍光タンパク質は、至適な波長の励起光を吸収することにより強い蛍光を発し、導入した細胞を生きたままの状態で可視化することができる。GFP（Green Fluorescent Protein）をはじめとする蛍光タンパク質を用いた分子イメージングは、最先端の生命科学の研究や技術開発には広範囲に利用されているが、医療への応用は未だ研究段階であり、実際にヒトに臨床応用された事例はない。われわれは、テロメラーゼ活性（hTERT遺伝子発現）に依存して癌細胞で選択的に増殖し細胞死を誘導する改変アデノウイルス製剤Telomelysin（開発コード：OBP-301）を開発し、米国にて臨床試験を行い、その安全性と臨床効果を確認した。このウイルスのゲノム配列は完全に明らかになっており、癌選択的ベクターとして外来遺伝子を搭載することができる。すなわち、蛍光タンパク質をコードする遺伝子を組み込み、癌細胞で選択的に蛍光発現を誘導することができる。

本研究では、テロメラーゼ活性依存性に癌細胞で選択的に増殖してGFP遺伝子を発現するナノバイオ・ウイルス製剤TelomeScan（OBP-401）を標識薬剤とし、鏡視下手術用の高感度蛍光感知ビデオスコープを用いたリアルタイム微小癌転移診断用の外科ナビゲーション・システムを開発する。また、GFPの蛍光波長より長く、組織透過性の高い近赤外蛍光を発する新しい蛍光タンパク質遺伝子を搭載した新規ウイルス標識薬剤を開発し、鏡視下手術時における有用性や汎用性をTelomeScanと比較検討する。術前に原発病巣や体腔に投与されたナノバイオ・ウイルス製剤は、微小転移巣で癌細胞に感染・増殖して選択的に蛍光を発するので、高感度蛍光検出ビデオスコープを用いてリアルタイムにハイビジョン・モニター上で可視化することができる。

本年度は、初年度に試作した高感度蛍光検出ビデオスコープでGFP蛍光が大動物で検出できるかどうかを確認し、さらに近赤外蛍光を発する新たな実験用遺伝子改変ウイルスを作成した。

B．研究方法

1）TelomeScan（OBP-401）の構造と機能

TelomeScanは幼児の「かぜ」症状の原因となるアデノウイルス5型を基本骨格とし、テロメラーゼ構成成分であるhTERT（human telomerase reverse transcriptase）遺伝子のプロモーターの下流にウイルス増殖に必須のE1AおよびE1B遺伝子がIRES配列で連結して組み込まれている。また、ウイルスゲノムのE3領域に、オワンクラゲ由来のGFP（Green Fluorescent Protein）蛍光発現遺伝子が挿入されている。TelomeScanは癌細胞で選択的に増殖してGFP蛍

光を発するとともに、最終的には細胞死を誘導する。一方、テロメラーゼ活性を持たない正常細胞では、その増殖は抑制され、GFPもみられず、細胞死も生じることはない。



図１　TelomeScanウイルスの構造

2）非増殖型GFP遺伝子発現アデノウイルス（Ad-GFP）の大動物への投与

GFP遺伝子発現による蛍光が、大動物の組織内で高感度に観察可能かどうかを確認する実験を行った。TelomeScanは癌組織においてのみ増殖しGFP蛍光を発するため、担癌状態にない正常なミニブタではウイルス増殖とGFP発現が期待できない。そこで、ミニブタの耳朶および腹部皮下にGFP遺伝子発現非増殖型アデノウイルス（Ad-GFP）を高容量で投与し、経時的に蛍光発現を観察した。

3）大動物におけるGFP遺伝子発現ヒト癌細胞の可視化の試み

非増殖型Ad-GFPをH1299ヒト肺癌細胞に感染させ、24-48時間後に遠心にて回収、ペレット状にして、全身麻酔下のミニブタに経口的内視鏡にて粘膜下に、あるいは開腹にて胃壁漿膜下に注入し、初年度に作成した高感度蛍光検出ビデオスコープ第2号機にて蛍光観察を行った。



図2　高感度蛍光観察ビデオスコープ第2号試作機

4）近赤外蛍光遺伝子発現ウイルス製剤の作成

GFPより深部の微小癌組織を高感度に検出するために、組織透過性の高い近赤外蛍光を発する蛍光タンパク質を搭載した新たなウイルス標識薬剤の作成を試みた。候補遺伝子として、GFPの蛍光波長505 nmより長く組織透過性の高い635 nmの近赤外蛍光を発するイソギンチャク*Entacmaea quadricolor*由来の新しい蛍光タンパク質Katushkaを用いた。

（倫理面への配慮）

制限増殖型ウイルス製剤を用いる本研究は「大臣確認実験」となるため、「第二種使用等拡散防止措置確認申請書」を作成、学内の担当部署での検討の後に文部科学省に申請し、研究計画実施の承認を得ている。

C．研究結果

1）非増殖型GFP遺伝子発現アデノウイルス（Ad-GFP）の大動物への投与

ミニブタの耳朶および腹部皮下にAd-GFPを高容量で投与し、経時的に蛍光発現を観察したところ、1週間後までGFP蛍光発現は認められなかった。ウイルス感染効率あるいは遺伝子発現効率が低いためと考えられる

2）大動物におけるGFP遺伝子発現ヒト癌細胞の可視化の試み

全身麻酔下のミニブタにGFP遺伝子発現H1299ヒト肺癌細胞をペレット状にして経口的内視鏡にて粘膜下に、あるいは開腹にて胃壁漿膜下に注入し、高感度蛍光検出ビデオスコープ第2号試作機にて腹腔内を観察したところ、GFP蛍光が明瞭に検出可能であった。



図3　蛍光観察ビデオスコープによる蛍光検出

3）近赤外蛍光遺伝子発現ウイルス製剤の作成

GFPより深部の微小癌組織を高感度に検出するために近赤外蛍光遺伝子Katushkaを搭載する非増殖型アデノウイルス（Ad-Katushka）の遺伝子改変を行

った。Ad-Katushkaを50 multiplicity of infection (MOI)でヒト胃癌細胞（MKN1、MKN45）、ヒト大腸癌細胞（SW620、SW480）に感染させたところ、48時間後に明瞭な近赤外蛍光発現が観察された。



（上段：MKN1、下段：MKN45）

図4　ヒト癌細胞における近赤外蛍光遺伝子発現

D．考察

蛍光タンパク質を用いた*in vivo*蛍光イメージングは、最先端の生命科学の研究に重要な技術であるが、医療の現場で実用化された事例はまだない。テロメラーゼ活性に反応して増殖する遺伝子改変アデノウイルスは80-100 nmの天然のバイオ・ナノマシーンであり、癌細胞で選択的に蛍光遺伝子を発現するために適したベクターと成り得る。投与されたウイルス標識薬剤はリンパ流や血流に乗って拡散し、微小転移病巣で増殖するとともに蛍光発現を生じる。高感度蛍光感知ビデオスコープを組み合わせることで鏡視下手術用外科ナビゲーション・システムの臨床応用が実現すれば、手術中にリアルタイムにリンパ節転移などの微小癌組織を同定することができ、必要最小限の領域を切除する超縮小手術の施行が可能となる。

たとえば早期消化器癌の場合、本技術による診査腹腔鏡や経管腔的内視鏡手術（NOTES、Natural Orifice Translumenal Endoscopic Surgery）で確実にリンパ節転移や播種がないことを確認できれば、原発巣は内視鏡的粘膜下切開術（ESD、Endoscopic Submucosal Dissection）のみで切除可能なケースも増えてくる。すなわち、本研究成果によって、外科切除範囲を最小限に留めることで大部分の臓器を温存したり、あるいはリンパ節郭清そのものを省略したりすることができれば、画期的な機能温存が可能となり、治療後の患者の生活の質の著しい向上に貢献することができる。

初年度である平成21年度は、GFPを可視化することができる高感度蛍光感知ビデオスコープの第1号試作機、および小型・軽量化した第2号試作機を作成した。カメラヘッドのスイッチにて明視野モードと蛍光モードのフィルター切り替えがワンタッチでできる、その切り替えに連動して光源フィルターとモニター表示が切り替わり、明視野と蛍光視野を切り替えて表示するシステムとした。全身麻酔下のミニブタで、経口的に挿入した消化管内視鏡で胃粘膜下にTelomeScanと同一の蛍光特性を持つ蛍光ビーズを注入したところ、腹腔内から第2号試作機にて極めて良好に胃から所属リンパ節へのリンパ流をリアルタイムに確認することができた。

研究2年目となる本年度は、高感度蛍光感知ビデオスコープ第2号試作機によるミニブタの組織における*GFP*遺伝子発現の検出を試みた。Ad-GFPの投与では蛍光発現はみられなかったが、細胞レベルでGFP発現していると高感度に検出可能であることが明らかとなった。このGFP蛍光は、平成19年度までに本研究課題にて試作した携帯型蛍光検出プローブにても同様に検出することができた。

また、近赤外Katushka蛍光遺伝子を挿入した非増殖型アデノウイルスベクター（Ad-Katushka）を作成し、各種ヒト癌細胞において近赤外蛍光の発現を確認した。当初、近赤外蛍光遺伝子を発現する癌特異的制限増殖型ウイルスの作成を試みる予定であったが、非担癌動物での発現は期待できないため、まず基盤研究としてAd-Katushkaを構築した。

今後は、蛍光感知ビデオスコープで緑色蛍光および近赤外蛍光が観察できるようにフィルター変換機能を付加し、Ad-GFP、Ad-Katushka、あるいはそれぞれを*ex vivo*で感染させたヒト癌細胞を投与して空間的検出能を含めたビデオスコープの機能解析を行う。さらに、Telomelysin（OBP-301）ウイルスゲノムのE3領域への近赤外蛍光遺伝子挿入を成功させ、腫瘍選択的近赤外蛍光発現ウイルスを完成させる。最終的には、診断用イメージング医薬品としてウイルスの製造確認申請と高感度GFP蛍光感知ビデオスコープの医療機器としての申請を計画し、外科ナビゲーション・システムとしての臨床試験の立案を行い、胃癌をはじめとする消化器癌治療現場への臨床展開を目指す。

E．結論

大動物において高感度蛍光検出ビデオスコープ試作機にてGFPの蛍光を可視化することができた。

F．研究発表

1. 論文発表

【英文】

1. Sugio, K., Sakurai, F., Katayama, K., Tashiro, K., Matsui, H., Kawabata, K., Kawase, A., Iwaki, M., Hayakawa, T., Fujiwara, T., Mizuguchi, H. Enhanced safety profiles of the telomerase-specific replication-competent adenovirus by incorporation of normal cell-specific microRNA-targeted sequences. ***Clin. Cancer Res.***, (in press), 2011.

2. Sasaki, T., Tazawa, H., Hasei, J., Kunisada, T., Yoshida, A., Hashimoto, Y., Yano, S., Yoshida, R., Uno, F., Kagawa, S., Morimoto, Y., Urata, Y., Ozaki, T., Fujiwara, T. Preclinical evaluation of telomerase-specific oncolytic virotherapy for human bone and soft tissue sarcomas. ***Clin. Cancer Res.***, 17: 1828-1838, 2011.
3. Umeda, Y., Matsuda, H., Sadamori, H., Shinoura, S., Yoshida, R., Sato, D., Utsumi, M., Yagi, T., Fujiwara, T. Leukoencephalopathy syndrome after living-donor liver transplantation. ***Exp. Clin. Transplant.***, 9: 139-144, 2011.
4. Motoki, T., Naomoto, Y., Hoshiba, J., Shirakawa, Y., Yamatsuji, T., Matsuoka, J., Takaoka, M., Tomono, Y., Fujiwara, Y., Tsuchita, H., Gunduz, M., Nagatsuka, H., Tanaka, N., Fujiwara, T. Glutamine depletion induces murine neonatal melena with increased apoptosis of the intestinal epithelium. ***World J. Gastroenterol.***, 17: 717-726, 2011.
5. Tazawa, H., Kagawa, S., Fujiwara, T. MicroRNA as potential target gene in cancer gene therapy of gastrointestinal tumors. ***Expert Opin. Biol. Th.***, 11: 145-155, 2011.
6. Fujiwara, T., Shirakawa, Y., Kagawa, S. Telomerase-specific oncolytic virotherapy for human gastrointestinal cancer. ***Expert Rev. Anticancer Th.***, 11: 525-532, 2011.
7. Kuroda, S., Fujiwara, T., Shirakawa, Y., Yamasaki, Y., Yano, S., Uno, F., Tazawa, H., Hashimoto, Y., Watanabe, Y., Noma, K., Urata, Y., Kagawa, S., Fujiwara, T. Telomerase-dependent oncolytic adenovirus sensitizes human cancer cells to ionizing radiation via inhibition of DNA repair machinery. ***Cancer Res.***, 70: 9339-9348, 2010.
8. Umeda, Y., Matsuda, H., Sadamori, H., Matsukawa, H., Yagi, T., Fujiwara, T. A prognostic model and treatment strategy for intrahepatic recurrence of hepatocellular carcinoma after curative resection. ***World J. Surg.***, 35: 170-177, 2011.
9. Sakai, R., Kagawa, S., Yamasaki, Y., Kojima, T., Uno, F., Hashimoto, Y., Watanabe, Y., Urata, Y., Tanaka, N., Fujiwara, T. Preclinical evaluation of differentially targeting dual virotherapy for human solid cancer. ***Mol. Cancer Ther.***, 9: 1884-1893, 2010.
10. Huang, P., Kaku, H., Chen, J., Kashiwakura, Y., Saika, T., Nasu, Y., Urata, Y., Fujiwara, T., Watanabe, M., Kumon, H. Potent antitumor effects of combined therapy with a telomerase-specific, replication-competent adenovirus (OBP-301) and IL-2 in a mouse model of renal cell carcinoma. ***Cancer Gene Ther.***, 17: 484-491, 2010.
11. Kojima, T., Watanabe, Y., Hashimoto, Y., Kuroda, S., Yamasaki, Y., Yano, S., Ouchi, M., Tazawa, H., Uno, F., Kagawa, S., Kyo, S., Mizuguchi, H., Urata, Y., Tanaka, N., Fujiwara, T. In vivo biological purging for lymph node metastasis of human colorectal cancer by telomerase-specific oncolytic virotherapy. ***Ann. Surg.***, 251: 1079-1086, 2010.
12. Watanabe, Y., Kojima, T., Kagawa, S., Uno, F., Hashimoto, Y., Kyo, S., Mizuguchi, H., Tanaka, N., Kawamura, H., Ichimaru, D., Urata, Y., Fujiwara, T. A novel translational approach for human malignant pleural mesothelioma: heparanase-assisted dual virotherapy. ***Oncogene***, 29:1145-1154, 2010.

【邦文】

1. 藤原俊義：テロメラーゼ活性を標的とする抗腫瘍ウイルス製剤の臨床開発：放射線感受性の増感作用. ***放射線生物研究*** 45: 23-34、2010.
2. 藤原俊義：消化器がん治療における先端医療開発. ***岡山医学会雑誌*** 122:209-213、2010.
3. 児島亨、橋本悠里、香川俊輔、田中紀章、浦田泰生、藤原俊義：制限増殖型アデノウイルス製剤を用いた新たな微小がん病変の検出法の開発と治療への応用（平成21年度岡山医学会賞（山田賞）受賞論文）. ***岡山医学会雑誌*** 122: 203—208、2010.

2. 学会発表

【国際学会】

1. Fujiwara, T. Molecular imging of human cancer with telomerase-specific replication-selective adenovirus. ***Pre-conference Satellite Meeting of World Molecular Imaging Conference "Shedding Light for Unveiling Life"***, Seoul, 2010.
2. Fujiwara, T., Uno, F., Hashimoto, Y., Shirakawa, Y., Nagasaka, T., Kagawa, S., Urata, Y. Detection of viable human circulating tumor cells using telomerase-specific GFP-expressing bioengineered adenovirus in patients with gastric cancer: A fiesibility study. ***2011 ASCO Gastrointestinal Cancer Symposium***, San Francisco, January, 2011.
3. Nagasaka, T., Goel, A., Taniguchi, N., Mori, Y., Shigeyasu, K., Yamada, E., Oka, T., Sun, D., Fujiwara, T. Power of fecal DNA methylation analysis: Does it lead to development of a noninvasive screening tool for pancreatic cancer? ***2011 ASCO Gastrointestinal Cancer Symposium***, San Francisco, January, 2011.
4. Yoshida, R., Uno, F., Kagawa, S., Fujiwara, T. Sensitization to trastuzumab via ADCC activation by exogenous expression of HER2 extracellular domain in HER2-negative human gastric cancer cells. ***9th International Gastric Cancer Congress***, Seoul, April, 2011.
5. Kagawa, S., Yano, S., Tazawa, H., Hashimoto, Y., Shirakawa, Y., Kuroda, S., Yamasaki, Y., Uno, F., Nagasaka, T., Kishimoto, H., Nishizaki, M., Urata, Y., Fujiwara, T. Three-dimensional visualization of eliminating human cancer stem cell by oncolytic adenovirus. ***9th International Gastric Cancer Congress***, Seoul, April, 2011.
6. Uno, F., Kagawa, S., Nishizaki, M., Kishimoto, H., Gouchi, A., Kimura, T., Takahata, T., Nonaka, Y., Ninomiya, M., Fujiwara, T. Phase II study of S-1 and docetaxel combination chemotherapy for advanced or recurrent gastric cancer with peritoneal dissemination. ***9th International Gastric Cancer Congress***, Seoul, April, 2011.
7. Nishizaki, M., Kagawa, S., Uno, F., Kishimoto, H., Gouchi, A., Fujiwara, T. A modified overlap method for performing Billroth-I anastomosis after laparoscopic distal gastrectomy. ***9th International Gastric Cancer Congress***, Seoul, April, 2011.

【国内学会】

1. 藤原俊義：テロメラーゼ活性を標的とするウイルス製剤の癌診断・治療への応用. ***第110回日本外科学会定期学術集会（ワークショップ「癌治療向上のための translational research」）***、名古屋、2010年4月.
2. 藤原俊義：Telomerase-specific molecular radiosensitizer for human cancer. ***第49回日本生体医工学会大会（オーガナイズドセッション「ナノテクノロジーと物理エネルギーを融合したハイブリッド標的化診断・治療」）***、大阪、2010年6月.

3. Fujiwara, T., Urata, Y., Nemunaitis, J. Phase I clinical trial of telomerase-specific oncolytic adenovirus for advanced solid tumors. ***第16回日本遺伝子治療学会（Main Symposium）***、宇都宮、2010年7月.
4. 藤原俊義、宇野太、田澤大、香川俊輔、児島亨、矢野修也、吉田亮介、橘本悠里、浦田泰生：遺伝子改変ウイルス製剤を用いた蛍光イメージングによる血中循環がん細胞（CTC）の検出. ***第65回日本消化器外科学会総会（パネルディスカッション「分子生物学を応用した消化器癌の悪性度診断」）***、山口、2010年7月.
5. 藤原俊義：Theranostic application of telomerase-specific replication-selective adenosurs for human cancer. ***第69回日本癌学会学術総会（モーニングレクチャー）***、大阪、2010年9月.
6. Tazawa, H., Yano, S., Yoshida, R., Urata, Y., Fujiwara, T. Oncolytic adenovirus induces autophagic cell death through microRNA-7-mediated suppression of EGFR in human cancer cells. ***第16回日本遺伝子治療学会***、宇都宮、2010年7月.
7. 橘本悠里、寺石文則、香川俊輔、宇野太、田澤大、矢野修也、浦田泰生、藤原俊義：Hypoxia promotes replication and therapeutic potency of telomerase-specific oncolytic adenovirus for human cancer cells. ***第69回日本癌学会学術総会***、大阪、2010年9月.
8. 永坂岳司、田中紀章、松原長秀、藤原俊義：Somatic hypermethylation of MSH2 is a frequent event in Lynch syndrome colorectal cancers. ***第69回日本癌学会学術総会***、大阪、2010年9月.
9. 田澤大、矢野修也、吉田亮介、浦田泰生、藤原俊義：E2F1-mediated microRNA-7 upregulation induces autophagic cell death through EGFR suppression during adenovirus infection. ***第69回日本癌学会学術総会***、大阪、2010年9月.
10. 矢野修也、田澤大、橘本悠里、宇野太、香川俊輔、浦田泰生、藤原俊義：Visualizing treatment dynamics that oncolytic adenovirus promotes cell cycle progression of quiescent cancer stem cells. ***第69回日本癌学会学術総会***、大阪、2010年9月.
11. 佐々木剛、田澤大、橘本悠里、国定俊之、森本裕樹、吉田晶、浦田泰生、尾崎敏文、藤原俊義：Telomerase-specific replication-selective virotherapy for bone and soft tissue sarcoma. ***第69回日本癌学会学術総会***、大阪、2010年9月.
12. 水本泰成、高倉正博、京哲、中村充宏、毎田佳子、橋本学、森紀子、保野由紀子、浦田泰生、藤原俊義、井上正樹：Effect of telomerase-specific replication-selective adenovirus on ovarian cancer stem cells. ***第69回日本癌学会学術総会***、大阪、2010年9月.
13. 高倉正博、京哲、中村充宏、毎田佳子、橋本学、森紀子、水本泰成、保野由紀子、橘本悠里、浦田泰生、藤原俊義、井上正樹：Detection of circulating tumor cells using telomerase-specific replication-selective adenovirus in gynecologic cancers. ***第69回日本癌学会学術総会***、大阪、2010年9月.
14. 合地明、藤原俊義、猿木信裕、坂東悦郎、大西始、今泉明、山本浩史、光島徹、山門實： AminoIndex, a novel screening marker based on plasma free amino acid profile, for gastric cancer screening. ***第69回日本癌学会学術総会***、大阪、2010年9月.

研究成果の刊行に関する一覧表

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Watanabe, Y., Kojima, T., Kagawa, S., Uno, F., Hashimoto, Y., Kyo, S., Mizuguchi, H., Tanaka, N., Kawamura, H., Ichimaru, D., Urata, Y., Fujiwara, T.	A novel translational approach for human malignant pleural mesothelioma: heparanase-assisted dual virotherapy.	**Oncogene**	29	1145-1154	2010
Kojima, T., Watanabe, Y., Hashimoto, Y., Kuroda, S., Yamasaki, Y., Yano, S., Ouchi, M., Tazawa, H., Uno, F., Kagawa, S., Kyo, S., Mizuguchi, H., Urata, Y., Tanaka, N., Fujiwara, T.	In vivo biological purging for lymph node metastasis of human colorectal cancer by telomerase-specific oncolytic virotherapy.	**Annals of Surgery**	251	1079-1086	2010
Sakai, R., Kagawa, S., Yamasaki, Y., Kojima, T., Uno, F., Hashimoto, Y., Watanabe, Y., Urata, Y., Tanaka, N., Fujiwara, T.	Preclinical evaluation of differentially targeting dual virotherapy for human solid cancer.	**Molecular Cancer Therapeutics**	9	1884-1893	2010
Kuroda, S., Fujiwara, T., Shirakawa, Y., Yamasaki, Y., Yano, S., Uno, F., Tazawa, H., Hashimoto, Y., Watanabe, Y., Noma, K., Urata, Y., Kagawa, S., Fujiwara, T.	Telomerase-dependent oncolytic adenovirus sensitizes human cancer cells to ionizing radiation via inhibition of DNA repair machinery.	**Cancer Research**	70	9339-9348	2010
Sasaki, T., Tazawa, H., Hasei, J., Kunisada, T., Yoshida, A., Hashimoto, Y., Yano, S., Yoshida, R., Uno, F., Kagawa, S., Morimoto, Y., Urata, Y., Ozaki, T., Fujiwara, T.	Preclinical evaluation of telomerase-specific oncolytic virotherapy for human bone and soft tissue sarcomas.	**Clinical Cancer Research**	17	1828-1838	2011
Tazawa, H., Kagawa, S., Fujiwara, T.	MicroRNA as potential target gene in cancer gene therapy of gastrointestinal tumors.	**Expert Opinion on Biological Therapy**	11	145-155	2011
Fujiwara, T., Shirakawa, Y., Kagawa, S.	Telomerase-specific oncolytic virotherapy for human gastrointestinal cancer.	**Expert Review of Anticancer Therapy**	11	525-532	2011

Oncogene (2010) 29, 1145–1154

www.nature.com/onc

ORIGINAL ARTICLE

A novel translational approach for human malignant pleural mesothelioma: heparanase-assisted dual virotherapy

Y Watanabe[1,2,3], T Kojima[3], S Kagawa[1,3], F Uno[1,3], Y Hashimoto[2,3], S Kyo[4], H Mizuguchi[5], N Tanaka[3], H Kawamura[2], D Ichimaru[2], Y Urata[2] and T Fujiwara[1,3]

[1]*Center for Gene and Cell Therapy, Okayama University Hospital, Okayama, Japan;* [2]*Oncolys BioPharma, Inc., Minato-ku, Tokyo, Japan;* [3]*Department of Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan;* [4]*Department of Obstetrics and Gynecology, Kanazawa University School of Medicine, Kanazawa, Japan and* [5]*Department of Biochemistry and Molecular Biology, Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan*

Malignant pleural mesothelioma (MPM) is a highly aggressive tumor that is related to asbestos exposure. MPM is characterized by rapid and diffuse local growth in the thoracic cavity, and it has a poor prognosis because it is often refractory to conventional therapy. Although MPM is an extraordinarily challenging disease to treat, locoregional virotherapy may be useful against this aggressive disease because of the accessibility by intrapleural virus delivery. In this study, we show that telomerase-specific, replication-selective adenovirus OBP-301 can efficiently infect and kill human mesothelioma cells by viral replication. Intrathoracic administration of virus significantly reduced the number and size of human mesothelioma tumors intrathoracically implanted into *nu/nu* mice. A high-definition, fluorescence optical imaging system with an ultra-thin, flexible fibered microprobe clearly detected intracellular replication of green fluorescent protein-expressing oncolytic virus in intrathoracically established mesothelioma tumors. As the extracellular matrix (ECM) may contribute to the physiological resistance of a solid tumor by preventing the penetration of therapeutic agents (including oncolytic viruses), we also examined whether the co-expression of heparanase, an endoglucuronidase capable of specifically degrading heparan sulfate, that influences the physiological barrier to macromolecule penetration, can modify the permeability of the ECM, resulting in profound therapeutic efficacy. Co-injection of OBP-301 and a replication-defective adenovirus (Ad-*S/hep*)-expressing heparanase resulted in more profound antitumor effects without apparent toxicity in an orthotopic pleural dissemination model. Our results suggest that intrathoracic dual virotherapy with telomerase-specific oncolytic adenovirus in combination with heparanase-expressing adenovirus may be efficacious in the prevention and treatment of pleural dissemination of human malignant mesothelioma.
Oncogene (2010) **29,** 1145–1154; doi:10.1038/onc.2009.415; published online 23 November 2009

Correspondence: Dr T Fujiwara, Center for Gene and Cell Therapy, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Okayama 700-8558, Japan.
E-mail: toshi_f@md.okayama-u.ac.jp
Received 12 July 2009; revised 23 September 2009; accepted 19 October 2009; published online 23 November 2009

Keywords: telomerase; adenovirus; mesothelioma; heparanase; dual virotherapy

Introduction

Malignant pleural mesothelioma (MPM) is an uncommon neoplasm with an annual estimated incidence of 2000–3000 new cases in the United States (Connelly *et al.*, 1987; Price, 1997). In more than 70% of patients, the origin of the tumor is linked to a history of exposure to asbestos fibers (Chahinian *et al.*, 1982; Chailleux *et al.*, 1988). The use of asbestos in Japan increased rapidly after the 1950s and remained at a high level even as the worldwide use of asbestos decreased substantially after the 1980s, therefore, the mortality rate for MPM is expected to continuously increase in Japan (Murayama *et al.*, 2006). MPM is characterized by progressive local tumor invasion and poor median survival ranging from 9 to 16 months (Ruffie *et al.*, 1989). MPM is notoriously refractory to treatment, and neither surgery nor radiotherapy alone results in increased survival (Ball and Cruickshank, 1990; Rusch *et al.*, 1991). Although many chemotherapeutic regimens have been suggested, a standard treatment strategy for MPM remains elusive (Alberts *et al.*, 1988; Ryan *et al.*, 1998). Therefore, the development of novel therapeutic options is required.

Clinical trials of patients with MPM have established the safety of the intrapleural delivery of replication-deficient adenoviral vectors expressing the suicide gene, herpes simplex thymidine kinase, followed by the administration of ganciclovir, an antiviral drug. Some evidence indicates that this approach induces an effective antitumor immune response (Sterman *et al.*, 1998, 2005; Molnar-Kimber *et al.*, 1998). Moreover, intrapleural interferon-ß gene transfer with a replication-defective adenoviral vector may potentially be a useful approach for the generation of antitumor immune responses in MPM patients (Sterman *et al.*, 2007). A significant obstacle to these approaches is the limited distribution of the non-replicative vectors within the tumor mass, even after direct intratumoral administration. Histopathological analyses have shown that these vectors transduce only a few tumor cells,

despite the successful antitumor responses. Therefore, more efficient strategies for the virus to spread within tumors may be required to increase the clinical benefit.

Replication-selective, tumor-specific viruses present a novel approach for the treatment of neoplastic diseases. These vectors are designed to induce virus-mediated lysis of tumor cells after selective viral propagation within the tumor. Telomerase activation is a critical step in carcinogenesis, and it correlates closely with human telomerase reverse transcriptase (hTERT) expression. We constructed an attenuated adenovirus 5 vector (OBP-301, Telomelysin), in which the hTERT promoter element drives expression of the *E1A* and *E1B* genes linked with an internal ribosome entry site. OBP-301 replicated efficiently and induced marked cell killing in a panel of human cancer cell lines, whereas replication as well as cytotoxicity was highly attenuated in normal human cells lacking telomerase activity (Kawashima *et al.*, 2004; Taki *et al.*, 2005). In this study, we examined the therapeutic potential of intrapleural delivery of OBP-301 against human MPM tumors intrathoracically implanted into *nu/nu* mice. As the extracellular matrix (ECM) may contribute to the physiological resistance of a solid tumor by preventing the penetration of therapeutic agents (including oncolytic viruses), we also examined whether the co-expression of heparanase, an endoglucuronidase capable of specifically degrading heparan sulfate, that influences the physiological barrier to macromolecule penetration, can modify the permeability of the ECM, resulting in profound therapeutic efficacy.

Results

Expression of CAR and hTERT levels in human mesothelioma cell lines

To examine the biological characteristics of human mesothelioma cells, we first used flow cytometry to determine the cell surface expression of coxsackie and adenovirus receptor (CAR). CAR was expressed in all four cell lines tested, although the expression levels varied (Figure 1b). H2052 and H2452 cells showed low,



Figure 1 Schematic DNA structures of telomerase-specific viruses and characteristics of human mesothelioma cell lines. (**a**) OBP-301 is a telomerase-specific, replication-competent adenovirus that contains the human telomerase reverse transcriptase (hTERT) promoter sequence inserted into the adenovirus genome to drive transcription of the E1A and E1B bicistronic cassette linked by internal ribosome entry site (IRES). OBP-401 is a variant of OBP-301 and contains the green fluorescent protein *(GFP)* gene inserted under the cytomegalovirus (CMV) promoter into the E3 region for monitoring viral replication. Ad-*S/hep* vector contains human heparanase complementary DNA (cDNA) driven by the CMV promoter. (**b**) Flow cytometric analysis of coxsackie and adenovirus receptor (CAR) expression in human mesothelioma cell lines. Cells were incubated with anti-CAR monoclonal antibodies followed by fluorescein isothiocyanate (FITC)-conjugated rabbit anti-mouse IgG (gray area). An isotype-matched normal mouse IgG conjugated to FITC was used as a control (black line). (**c**) Relative *hTERT* messenger RNA (mRNA) expression in human mesothelioma cell lines and normal cell lines was determined by real-time reverse transcription (RT)–PCR analysis. The *hTERT* mRNA expression of H1299 human lung cancer cells was considered 1.0, and the relative expression level of each cell line was calculated against that of H1299 cells.



Figure 2 Selective cytopathic effect of OBP-301 in human mesothelioma cell lines *in vitro*. Cells were infected with OBP-301 at the indicated multiplicity of infection (MOI) values, and the surviving cells were quantitated over 5 days by XTT assay. The cell viability of mock-treated cells on day 1 was considered 1.0, and the relative cell viability was calculated. Values represent the mean ± s.d. of triplicate experiments.

but detectable CAR expression compared with CAR-negative cell lines such as LN444, LNZ308 and H1299R5 that we reported earlier (Tango *et al.*, 2004; Taki *et al.*, 2005). A real-time reverse transcription–PCR method showed that all cell lines expressed detectable levels of *hTERT* messenger RNA (mRNA), suggesting that the hTERT promoter element can be used to target human mesothelioma cells (Figure 1c).

In vitro *cytopathic efficacy of OBP-301 on human mesothelioma cell lines*

To determine whether OBP-301 infection induces selective cell lysis, mesothelioma cells were infected with OBP-301 at various multiplicity of infections (MOIs), and then the XTT cell viability assay was performed over 5 days. All mesothelioma cell lines were efficiently killed by OBP-301 in a dose-dependent manner (Figure 2). Infection at an MOI of 10 was sufficient to induce cell lysis within 3 days. To visually confirm the viral replication and spread, we modified OBP-301 to express the green fluorescent protein (*GFP*) reporter gene under the control of the cytomegalovirus promoter in the E3 region (modified virus, OBP-401) (Figure 1a). We have confirmed earlier that the propagation and yields of OBP-301 and OBP-401 are equivalent (Kawashima *et al.*, 2004; Kishimoto *et al.*, 2006). After OBP-401 infection, phase-contrast images showed a rapid loss of viability because of massive cell death, as evidenced by ballooning and floating cells. We observed a strong and persistent GFP fluorescence expression in these mesothelioma cells under a fluorescence microscope, indicating the viral replication and spread into the neighboring tumor cells (Figure 3a).

Intrathoracic virus spread and infection in an orthotopic pleural human mesothelioma model

We also evaluated the viral infection and replication in human mesothelioma cells growing intrathoracically in athymic *nu/nu* mice. When H2052 and H2452 mesothelioma cells were inoculated into the thoracic space, disseminated tumor nodules were detected in the visceral pleura, parietal pleura, diaphragmatic pleura and mediastinum. We used H2452 cells with low CAR and *hTERT* mRNA expression that were considered to be most refractory to OBP-301 for the further *in vivo* experiments. Tumor weights at autopsy more than 40 days after tumor cell inoculation were significantly greater than tumor weights at <30 days, indicating the tumor growth in the thoracic cavity (Supplementary Figure 1). Optical charged-coupled device imaging detected GFP-labeled tumors at the gross level during a midsternal thoracotomy 6 days after intrathoracic injection of 1×10^8 plaque-forming units (PFU) of OBP-401. Moreover, GFP expression in macroscopically invisible tumors could be detected at the microscopic level with a hand-held flexible probe inserted through



Figure 3 Visualization of human mesothelioma cells *in vitro* and *in vivo* by OBP-401 infection. (**a**) H2052, H2452, H28 and 211 H cells were infected with OBP-401 at an multiplicity of infection (MOI) of 10. Cell morphology and green fluorescent protein (GFP) expression were evaluated by fluorescence microscopy at the indicated time. Bar = 200 μm. (**b**) Internal images of pleural mesothelioma dissemination visualized by intrathoracic injection of OBP-401. Six weeks after intrathoracic inoculation of 5×10^6 H2452 cells, mice received an intrathoracic injection of 1×10^9 plaque-forming units (PFU) of OBP-401. The GFP fluorescence expression was detected 6 days after virus administration by a 3-charged-coupled device (CCD) camera (top panels) and an *in situ* molecular imaging system (bottom panels). Top-left panel, gross appearance of disseminated H2452 tumors; top-right panel, fluorescent detection. Bottom panels, I, II and III represent the boxed regions of the top panels. Bar = 30 μm. (**c**) Histologic sections stained with hematoxylin and eosin showing local growth of H2452 mesothelioma cells (arrows) in the thoracic spaces. Top panels, ×40 magnification; bottom panels, ×400 magnification. I and II represent the boxed regions of (**b**).

the intercostal small incision (Figure 3b and Supplementary Figure 2). Histological analysis confirmed the presence of disseminated tumors in the sites of fluorescence emission (Figure 3c). These results suggest that intrathoracically injected oncolytic virus can infect and selectively replicate in disseminated tumor tissues.

In vivo *antitumor effect of intrathoracic delivery of OBP-301 in an orthotopic pleural human mesothelioma model*
To examine the therapeutic effect of telomerase-specific oncolytic virus, mice received an injection of 1×10^7 or 1×10^8 PFU of OBP-301, 1×10^8 PFU of replication-defective control adenovirus (dl312), or phosphate-buffered saline into the thoracic spacethe injections were administered twice at a 1-week interval beginning 24 h after tumor cell inoculation. Injection of 10^8 PFU of OBP-301 significantly reduced the incidences of tumor cell dissemination and the total weights of tumor nodules as compared with mice that received dl312 or phosphate-buffered saline injection, although 10^7 PFU of OBP-301 had no apparent effect (Figures 4a and b). Next, we examined treatment schedules with different starting points. Two injections of 1×10^8 PFU of OBP-301 administered at a 1-week interval starting on day 1, 8, 22 or 29 after tumor inoculation showed statistically significant antitumor effects when mice were killed on day 43 (Figure 4c and Supplementary Figure 3). These results suggest that oncolytic virotherapy could be



Figure 4 *In vivo* antitumor effect of OBP-301 on pleural dissemination of H2452 human mesothelioma cells. (**a**) Gross appearance of H2452 tumors grown orthotopically in the thoracic spaces. H2452 cells (5×10^6) were inoculated into the thoracic space of athymic *nu/nu* mice. After 24 h, either 1×10^7 plaque-forming units (PFU)/100 μl or 1×10^8 PFU/100 μl of OBP-301, 1×10^8 PFU/100 μl of dl312 (replication-deficient adenovirus), or phosphate-buffered saline (PBS) were injected into the thoracic space twice at a 1-week interval (total dose: 2×10^7 or 2×10^8 PFU). Eight weeks after tumor cell inoculation, the mice were killed, and the pleural dissemination of the thoracic spaces was assessed. (**b**) The weight of each tumor nodule found in the thoracic spaces was determined. Closed circles: individual tumor weights. Bars: mean weight. $*P<0.05$, $**P<0.01$. (**c**) The antitumor effect of OBP-301 administered in different treatment schedules was also assessed on an orthotopic pleural dissemination model. Top panel, treatment schedule. Bottom panel, tumor weight of each tumor nodule found in the thoracic spaces after treatment. The treated mice were killed and assessed for pleural dissemination 43 days after tumor inoculation. Closed circles: individual tumor weights. Bars: mean weight. $*P<0.05$.

effective for preventing the dissemination of mesothelioma cells as well as shrinking established tumors; complete eradication of disseminated nodules, however, was not achieved.

Enhanced antitumor effect of OBP-301 in combination with heparanase-expressing adenovirus in an orthotopic pleural human mesothelioma model

To further enhance the *in vivo* therapeutic potential of telomerase-specific virotherapy, we examined the combination effect of OBP-301 and a replication-defective adenovirus vector expressing the human *heparanase* gene (Ad-*S/hep*) (Uno *et al*., 2001). Heparan sulfate is a major constituent of the ECM that is responsible for a barrier to macromolecular diffusion in tumors. Thus, heparanase-mediated ECM degradation may be a critical requisite for virus penetration and distribution into tumor tissues. Western blot analysis revealed the expression of both proheparanase (*Mr* 65 000) and cleaved, active heparanase (*Mr* 50 000) in H2542 cells after Ad-*S/hep* infection expression of these proteins was not affected by the presence of OBP-301 (Figure 5a). In addition, an *in vitro* XTT analysis showed that co-infection of Ad-*S/hep* at various MOIs did not affect OBP-301-mediated cytotoxicity on human mesothelioma cells (Supplementary Figure 4).

We next examined whether heparanase expression enhanced the virus penetration into three-dimensional tumor structures using a human mesothelioma spheroid model. Tumor spheroids provide an excellent *in vitro* three-dimensional model resembling *in vivo* tumor masses for visualizing the dynamics of the virus and



Figure 5 Enhanced penetration of the virus into tumor spheroids by heparanase expression. (**a**) Western blot analysis of human heparanase protein expression in H2452 cells. Cells were infected with either dl312, Ad-*S/hep*, OBP-301 or OBP-301 in combination with Ad-*S/hep* at different multiplicity of infections (MOIs), as indicated. Equivalent amounts of protein obtained from whole cell lysates 30 h after infection were separated by electrophoresis, probed with primary antibodies, and then visualized by using an ECL detection system. Equal loading of samples was confirmed by reprobing with anti-actin antiserum. Both inactive (*Mr* 65 000) and active (*Mr* 50 000) forms of heparanase proteins were detected. (**b**, **c**) Transduction efficiency and viral spread of OBP-401 in combination with Ad-*S/hep* in H2452 tumor spheroids. H2452 tumor spheroids were infected with dl312 (replication-deficient adenovirus) or Ad-*S/hep* at 1×10^5 plaque-forming units (PFU), followed by infection with OBP-401 at 1×10^4 PFU 48 h later. Green fluorescent protein (GFP) expression in each tumor spheroid was assessed with a laser-scanning confocal fluorescent microscope 48 h later. (**b**) Gross imaging of H2452 tumor spheroids. (**c**) Higher magnification to show the surface area of the spheroids.

assessing the levels of virus penetration. Sequential confocal fluorescent microscopy showed that OBP-401 could penetrate and express GFP fluorescence in H2452 spheroids; GFP expression, however, could be detected in the deeper areas of the spheroids in the presence of Ad-*S/hep* (Figure 5b, c). High-magnification images showed that GFP signals were detected only at the spheroid surface after OBP-401 and control dl312 exposure, whereas co-infection of Ad-*S/hep* enhanced the OBP-401 penetration, leading to GFP expression in multiple layers.

Finally, we assessed the combination effect of OBP-301 and Ad-*S/hep* in an orthotopic pleural human mesothelioma model. Intrathoracic injection with 1×10^8 PFU of OBP-301 plus 1×10^7 PFU of Ad-*S/hep* on days 8 and 15 resulted in a significant reduction of tumor weights on day 43 (Figure 6a). This combination therapy showed greater antitumor effects than the therapy with 10^8 PFU of OBP-301 alone. The administration of Ad-*S/hep* alone did not affect tumor weights as compared with the tumors in the mock-treated group. Moreover, only one of the seven (14.3%) mice injected with OBP-301 alone survived over a 12-week observation period, whereas five of the seven (71.4%) mice treated with OBP-301 plus Ad-*S/hep* remained alive (Figure 6b).

Discussion

Malignant pleural mesothelioma is an aggressive neoplasm with a dismal prognosis because of its resistance



Figure 6 Enhanced antitumor effect of OBP-301 with Ad-*S/hep* in an orthotopic pleural dissemination model. (**a**) Top panel, treatment schedule. Bottom panel, tumor weight of each tumor nodule found in the thoracic spaces after treatment. Treated mice were killed and assessed for pleural dissemination 43 days after tumor inoculation. Closed circles: individual tumor weights. Bars: mean weight. $*P<0.05$. (**b**) Mice bearing H2452 xenografts in the thoracic spaces received intrathoracic administration of either OBP-301 plus dl312 or OBP-301 plus Ad-*S/hep*. Their post-treatment survival was monitored and plotted as a Kaplan–Meier plot.

to therapeutic modalities such as chemotherapy and radiotherapy. An alternative therapeutic option is the use of gene- and vector-based therapies. MPM is characterized by intrathoracic spread, and it is clinically accessible, making it an attractive target for locoregional delivery of genetically engineered viral agents. Replication-competent viral agents can confer specificity of infection and increase viral spread to neighboring tumor cells. Onyx-015, a conditional replication-competent adenovirus lacking the 55-kDa *E1b* gene, may be an effective treatment for human mesothelioma cells retaining wild-type p53 but lacking $p14^{ARF}$ (Ries *et al.*, 2000; Yang *et al.*, 2000, 2001), the targets of Onyx-015, however, are not general and its clinical trials for various types of human malignancies have been discontinued (Goodrum and Ornelles, 1998). In this study, we showed that intrathoracic administration of telomerase-specific oncolytic viruses induced significant antitumor effects against both pre-established and established pleural dissemination of human MPM. Moreover, we found that co-infection of oncolytic adenoviruses with non-replicative adenovirus expressing an ECM-digestive enzyme, heparanase, resulted in a virus distribution into the deeper areas of tumor spheroids, with substantial tumor weight reduction and enhanced efficacy in an orthotopic *in vivo* mesothelioma model.

For the success of gene- and vector-based therapies, it is critical to develop strategies to improve the vector distribution within tumors *in vivo*. Oncolytic viruses can mediate infected cell death, release viral progeny for propagation of infection and induce resultant lysis of neighboring tumor cells. Therefore, these viruses should have a more profound therapeutic efficacy even without particular therapeutic genes when compared with non-replicative viral vectors. Indeed, as human malignant mesothelioma cells express sufficient telomerase activity as well as CAR (Figure 1), most of the disseminated nodules were imaged with GFP fluorescence by intrathoracic administration of GFP-expressing, telomerase-specific OBP-401 in an orthotopic pleural mesothelioma model, which coincided with histologically confirmed mesothelioma (Figure 3). We have recently shown that this OBP-401-mediated GFP-labeling strategy is extremely sensitive to detect disseminated nodules and applicable for the surgical navigation (Kishimoto *et al.*, 2009). A confocal fluorescent imaging system with fibered microprobes showed that OBP-401 could also identify macroscopically invisible tumor tissues, suggesting that OBP-301 might be able to eliminate microscopic dissemination. In fact, local administration of OBP-301 into the thoracic cavity significantly suppressed the disseminated tumor growth (Figure 4). The treatment immediately after mesothelioma

cell inoculation resembles the state of a minimum residual disease after extended surgical excision. Most of the floating mesothelioma cells could be efficiently treated by locoregional OBP-301 administration, resulting in little disseminated tumor nodule formation. Tumor weights, however, increased gradually as the treatment time was delayed (Figure 4c), suggesting that some additional approaches are required to improve the therapeutic efficacy.

Extracellular matrix is a major barrier to macromolecular transport in the tumor interstitium, but digestive enzymes that degrade ECM may overcome the limited spread of viral agents within tumors. Previous studies have shown that protease that degrades multiple ECM components as well as collagenase that digests fibrillar collagen can mediate a broad distribution of virus particles within tumors, leading to enhanced therapeutic efficacy (Kuriyama *et al.*, 2001; McKee *et al.*, 2006). Non-replicating adenovirus vector expressing the matrix metalloproteinase-8 (MMP-8), which effectively degrades collagen-I, was also able to modify a fibrillar collagen substrate to allow oncolytic virus diffusion into tumors (Cheng *et al.*, 2007). More recent studies have also shown that relaxin-expressing, replication-competent adenovirus could increase the virus distribution and show a profound antitumor effect in mice (Kim *et al.*, 2006; Ganesh *et al.*, 2007). Although the most effective enzyme for the promotion of viral penetration into tumor masses has not been determined, we used heparanase, which has a hydrolytic mechanism to cleave glycosidic bonds in the heparan sulfate component of the ECM (McKenzie, 2007).

The expression of functional heparanase degrades the ECM, which in turn improves the uptake and distribution of biological agents including antibodies and viruses (Eikenes *et al.*, 2004). An advantage of heparanase is that other enzymes that are capable of digesting ECM and basement membrane components (such as MMP-2 and MMP-8) can be subsequently induced after heparanase expression. We reported earlier that the over-expression of the heparanase gene upregulated *MMP-2* mRNA expression in human lung cancer cells (Uno *et al.*, 2001). Arterial injury also increased heparanase activity in vascular endothelial cells, which was associated with MMP-2 and MMP-9 activation (Fitzgerald *et al.*, 1999). Therefore, a more prominent virus infiltration through broad ECM degradation with multiple enzymes can be expected by exogenous heparanase expression. The co-infection of Ad-*S/hep* considerably enhanced OBP-401 virus penetration into the multicellular spheroids, mimicking the *in vivo* biology of tumors (Figure 5b, c). Furthermore, combination therapy with OBP-301 and Ad-*S/hep* in an orthotopic murine model significantly reduced the tumor weights of disseminated plural mesothelioma as compared with tumors from mice treated with OBP-301 alone (Figure 6a), suggesting that heparanase-assisted broad virus distribution could mediate a more profound antitumor effect against human malignant mesothelioma.

Our data indicate that this dual virotherapy may be a promising therapeutic strategy for malignant pleural mesothelioma. However, the over-expression of ECM-digesting enzymes may potentially promote the metastasis of tumor cells. MMPs as well as heparanase were detected in many types of human cancer, and their expression has a very active role in tumor invasion and metastasis. Indeed, targeted inhibition of heparanase expression by antisense complementary DNA transfection showed a significant reduction in the invasive and metastatic properties of tumor cells in an animal model (Uno *et al.*, 2001). Short hairpin RNAs that mediated the attenuation of MMP expression also prevented the progression of human tumor cells *in vivo* (Blackburn *et al.*, 2007). Although there is a risk that the metastatic potential of tumor cells may be increased by heparanase expression, we found that the intrathoracic administration of 10^7 PFU of Ad-*S/hep* alone had no apparent effects on the growth of pleural mesothelioma, indicating that this particular dose of the virus appears to be safe (Figure 6a). In the dual-vector system, the two viral loads can be adjusted according to the function of each virus. We showed earlier that telomerase-specific oncolytic viruses and non-replicative adenovirus-expressing functional genes can successfully work together by determining the optimal doses of vectors (Umeoka *et al.*, 2004; Hioki *et al.*, 2008). A single oncolytic virus vector-expressing relaxin inhibits tumor growth and metastasis, however, it may be impossible to reduce the amount of relaxin expression when high doses of the virus are used. In contrast, our dual-vector system of telomerase-specific oncolytic adenovirus in combination with heparanase-expressing replication-deficient adenovirus can be used safely by a fine adjustment of the optimal doses.

In conclusion, our data clearly indicate that telomerase-specific oncolytic adenoviruses have significant therapeutic potential against human malignant pleural mesothelioma *in vitro* and *in vivo*. Moreover, the addition of heparanase-expressing adenovirus significantly enhanced the virus distribution and the antitumor effects of oncolytic adenoviruses. A phase I, dose-escalation study of telomerase-specific oncolytic adenovirus, OBP-301, is currently underway in the United States to assess the treatment feasibility and to characterize its pharmacokinetics in patients with advanced solid tumors (Fujiwara *et al.*, 2008). Phase II studies of telomerase-specific virotherapy in malignant pleural mesothelioma patients are warranted.

Materials and methods

Cell lines and culture conditions

The human mesothelioma cell lines H2052, H2452, H28 and 211H were purchased from American Type Culture Collection (Manassas, VA, USA). H2052 and H2452 cells were cultured as monolayers in RPMI 1640 medium supplemented with 10% fetal bovine serum, 100 units/ml penicillin and 100 mg/ml streptomycin. H28 and 211H were routinely propagated in monolayer culture in RPMI 1640 medium supplemented with 10% fetal bovine serum, 1 mM sodium pyruvate, 100 units/ml penicillin and 100 mg/ml streptomycin. The human non-small-cell lung cancer cell line H1299 was also cultured in RPMI

1640 medium supplemented with 10% fetal bovine serum, 100 units/ml penicillin and 100 mg/ml streptomycin. The normal human lung diploid fibroblast cell line WI38 (JCRB0518) was obtained from the Health Science Research Resources Bank (Osaka, Japan) and grown in Eagle's MEM with 10% fetal bovine serum. The normal human lung fibroblast and the human umbilical vascular endothelial cell line (TaKaRa Biomedicals, Shiga, Japan) were cultured according to the vendors' specifications.

Recombinant adenoviruses

OBP-301 is a telomerase-specific replication-compenent adenovirus variant, in which the hTERT promoter element drives the expression of *E1A* and *E1B* genes linked with internal ribosome entry site (Figure 1a). OBP-301 was modified to create OBP-401 for monitoring viral replicationthe *GFP* gene was inserted under the cytomegalovirus promoter into the E3 region to create OBP-401. Ad-*S/hep* is a replication-deficient adenovirus expressing the human *heparanase* gene under the cytomegalovirus promoter. The E1A-deleted adenovirus dl312 was used as the control adenovirus.

Flow cytometric analysis

A total of 2×10^5 cells were labeled with mouse monoclonal anti-CAR (RmcBUpstate Biotechnology, Lake Placid, NY, USA) for 30 min at 4 °C. Then, the cells were incubated with fluorescein isothiocyanate-conjugated rabbit anti-mouse IgG second antibody (Zymed Laboratories, South San Francisco, CA, USA) and analysed by flow cytometry (FACSCalibur, Becton Dickinson, Mountain View, CA, USA). An isotype-matched normal mouse IgG_1 conjugated to fluorescein isothiocyanate (Serotec, Oxford, UK) was used as a control.

Quantitative real-time PCR analysis of hTERT mRNA

Total RNA from the culture cells was obtained by using the RNeasy Mini Kit (Qiagen, Chatsworth, CA, USA). Approximately 0.1 μg of total RNA was used for reverse transcription. Reverse transcription was performed at 22 °C for 10 min and then at 42 °C for 20 min. The *hTERT* mRNA copy number was determined by real-time quantitative reverse transcription–PCR using a LightCycler instrument and a LightCycler DNA TeloTAGGG hTERT Quantification Kit (Roche Molecular Diagnostics, Indianapolis, IN, USA). Data analysis was performed using the LightCycler software. The ratios normalized by dividing the value of untreated cells were presented for each sample.

Cell viability assay

The XTT assay was performed to measure cell viability. Briefly, cells were seeded at 1×10^3 cells/well in 96-well plates 16–20 h before viral infection and infected with OBP-301 at a MOI of 0, 1, 10 or 50 PFU/cell. Cell viability was determined at the indicated times by using a Cell Proliferation Kit II (Roche Applied Science, Mannheim, Germany) according to the manufacturer's protocol.

Fluorescent microscopy

Human mesothelioma cell lines were infected with 10 MOI of OBP-401 *in vitro*. Expression of the *GFP* gene was assessed and photographed using an IX71 fluorescent microscope (Olympus, Tokyo, Japan) at indicated times.

Western blot analysis

H2452 cells were collected by trypsinization and washed twice in cold phosphate-buffered saline. Cells then were dissolved in lysis buffer containing 50 mM Tris–HCl (pH7.5), 150 mM NaCl, 0.5% Triton X-100, and protease inhibitors (0.2 mM phenylmethylsulfonyl fluoride, 0.2 mM 4-(2-aminoethyl)benzenesul-fonyl-fluoride, 10 μg/ml leupeptin, 10 μg/ml pepstatin, and 1 μg/ml aprotinin).The lysis was performed at 4 °C for 30 min, and then the reaction mixture was centrifuged at 15 000 revolutions per minute. The protein concentration of the supernatant was determined by using the Bio-Rad protein determination method (Bio-Rad, Hercules, CA, USA). Equal amounts (60 μg) of proteins were electrophoresed under reducing conditions on 12% (w/v) polyacrylamide gels. Proteins were electrophoretically transferred to Hy-bond-polyvinylidene diflouride transfer membranes (Amersham, Arlington Heights, IL, USA) and incubated with primary antibodies against heparanase or β-actin, and then peroxidase-linked secondary antibody. An enhanced chemiluminescence Western system (Amersham, Tokyo, Japan) was used to detect secondary probes.

Spheroid culture

Single-cell suspensions of H2452 cells were obtained by trypsinization of monolayer cultures that consisted of 1×10^4 cells seeded on SUMILON Celltight Spheroid (Sumitomo Bakelite Co, Tokyo, Japan) according to the manufacturer's protocol. After formation of small spheroidal aggregates, 1×10^3 PFU of Ad-*S/hep* or dl312 were added to the culture, followed by the addition of 1×10^4 PFU of OBP-401 48 h later. The GFP expression in each tumor spheroid was assessed under the laser-scanning confocal fluorescent microscope (Carl Zeiss, Jena, Germany) 48 h later.

Animal experiments

The experimental protocol was approved by the ethics review committee for animal experimentation of our institution. We used a 27-gauge needle to intrathoracically inject female BALB/c *nu/nu* mice with 100 μl of suspension containing 5×10^6 H2452 cells. The same technique was used for each viral injection into the thoracic space at the indicated time points. Mice were killed and their thoracic spaces were examined macroscopically. Tumor nodules in the thoracic spaces were removed and weighted. *In vivo* GFP fluorescence imaging was also acquired by using a Hamamatsu C5810 three-chip color cooled charged-coupled device camera (Hamamatsu Photonics Systems, Hamamatsu, Japan) and an *in situ* molecular imaging system (Cell ~ VIZIOMauna Kea Technologies, Paris, France).

Statistical analysis

We used the Student's *t*-test to determine statistically significant differences among the groups. *P*-values <0.05 were considered statistically significant.

Conflict of interest

Yasuo Urata is an employee of Oncolys BioPharma, Inc., the manufacturer of OBP-301 and OBP-401. Toshiyoshi Fujiwara is a consultant of Oncolys BioPharma, Inc.

Acknowledgements

We thank for K Nagai for his helpful discussion. We also thank Y Shirakiya, N Mukai, T Sueishi and M Yokota for their excellent technical support. The Cell ~ VIZIO system was provided by Mauna Kea Technologies (Paris, France).

References

Alberts AS, Falkson G, Goedhals L, Vorobiof DA, Van der Merwe CA. (1988). Malignant pleural mesothelioma: a disease unaffected by current therapeutic maneuvers. *J Clin Oncol* **6**: 527–535.

Ball DL, Cruickshank DG. (1990). The treatment of malignant mesothelioma of the pleura: review of a 5-year experience, with special reference to radiotherapy. *Am J Clin Oncol* **13**: 4–9.

Blackburn JS, Rhodes CH, Coon CI, Brinckerhoff CE. (2007). RNA interference inhibition of matrix metalloproteinase-1 prevents melanoma metastasis by reducing tumor collagenase activity and angiogenesis. *Cancer Res* **67**: 10849–10858.

Chahinian AP, Pajak TF, Holland JF, Norton L, Ambinder RM, Mandel EM. (1982). Diffuse malignant mesothelioma. Prospective evaluation of 69 patients. *Ann Intern Med* **96**: 746–755.

Chailleux E, Dabouis G, Pioche D, de LM, de Lajartre AY, Rembeaux A *et al.* (1988). Prognostic factors in diffuse malignant pleural mesothelioma. A study of 167 patients. *Chest* **93**: 159–162.

Cheng J, Sauthoff H, Huang Y, Kutler DI, Bajwa S, Rom WN *et al.* (2007). Human matrix metalloproteinase-8 gene delivery increases the oncolytic activity of a replicating adenovirus. *Mol Ther* **15**: 1982–1990.

Connelly RR, Spirtas R, Myers MH, Percy CL, Fraumeni Jr JF. (1987). Demographic patterns for mesothelioma in the United States. *J Natl Cancer Inst* **78**: 1053–1060.

Eikenes L, Bruland OS, Brekken C, Davies CL. (2004). Collagenase increases the transcapillary pressure gradient and improves the uptake and distribution of monoclonal antibodies in human osteosarcoma xenografts. *Cancer Res* **64**: 4768–4773.

Fitzgerald M, Hayward IP, Thomas AC, Campbell GR, Campbell JH. (1999). Matrix metalloproteinase can facilitate the heparanase-induced promotion of phenotype change in vascular smooth muscle cells. *Atherosclerosis* **145**: 97–106.

Fujiwara T, Tanaka N, Numunaitis JJ, Senzer NN, Tong A, Ichimaru D *et al.* (2008). Phase I trial of intratumoral administration of OBP-301, a novel telomerase-specific oncolytic virus, in patients with advanced solid cancer: Evaluation of biodistribution and immune response. *J Clin Oncol* **26**: 3572.

Ganesh S, Gonzalez EM, Idamakanti N, Abramova M, Vanroey M, Robinson M *et al.* (2007). Relaxin-expressing, fiber chimeric oncolytic adenovirus prolongs survival of tumor-bearing mice. *Cancer Res* **67**: 4399–4407.

Goodrum FD, Ornelles DA. (1998). p53 status does not determine outcome of E1B 55-kilodalton mutant adenovirus lytic infection. *J Virol* **72**: 9479–9490.

Hioki M, Kagawa S, Fujiwara T, Sakai R, Kojima T, Watanabe Y *et al.* (2008). Combination of oncolytic adenovirotherapy and Bax gene therapy in human cancer xenografted models. Potential merits and hurdles for combination therapy. *Int J Cancer* **122**: 2628–2633.

Kawashima T, Kagawa S, Kobayashi N, Shirakiya Y, Umeoka T, Teraishi F *et al.* (2004). Telomerase-specific replication-selective virotherapy for human cancer. *Clin Cancer Res* **10**: 285–292.

Kim JH, Lee YS, Kim H, Huang JH, Yoon AR, Yun CO. (2006). Relaxin expression from tumor-targeting adenoviruses and its intratumoral spread, apoptosis induction, and efficacy. *J Natl Cancer Inst* **98**: 1482–1493.

Kishimoto H, Kojima T, Watanabe Y, Kagawa S, Fujiwara T, Uno F *et al.* (2006). *In vivo* imaging of lymph node metastasis with telomerase-specific replication-selective adenovirus. *Nat Med* **12**: 1213–1219.

Kishimoto H, Zhao M, Hayashi K, Urata Y, Tanaka N, Fujiwara T *et al.* (2009). *In vivo* internal tumor illumination by telomerase-dependent adenoviral GFP for precise surgical navigation. *Proc Natl Acad Sci USA* **106**: 14514–14517.

Kuriyama N, Kuriyama H, Julin CM, Lamborn KR, Israel MA. (2001). Protease pretreatment increases the efficacy of adenovirus-mediated gene therapy for the treatment of an experimental glioblastoma model. *Cancer Res* **61**: 1805–1809.

McKee TD, Grandi P, Mok W, Alexandrakis G, Insin N, Zimmer JP *et al.* (2006). Degradation of fibrillar collagen in a human melanoma xenograft improves the efficacy of an oncolytic herpes simplex virus vector. *Cancer Res* **66**: 2509–2513.

McKenzie EA. (2007). Heparanase: a target for drug discovery in cancer and inflammation. *Br J Pharmacol* **151**: 1–14.

Molnar-Kimber KL, Sterman DH, Chang M, Kang EH, ElBash M, Lanuti M *et al.* (1998). Impact of preexisting and induced humoral and cellular immune responses in an adenovirus-based gene therapy phase I clinical trial for localized mesothelioma. *Hum Gene Ther* **9**: 2121–2133.

Murayama T, Takahashi K, Natori Y, Kurumatani N. (2006). Estimation of future mortality from pleural malignant mesothelioma in Japan based on an age-cohort model. *Am J Ind Med* **49**: 1–7.

Price B. (1997). Analysis of current trends in United States mesothelioma incidence. *Am J Epidemiol* **145**: 211–218.

Ries SJ, Brandts CH, Chung AS, Biederer CH, Hann BC, Lipner EM *et al.* (2000). Loss of p14ARF in tumor cells facilitates replication of the adenovirus mutant dl1520 (ONYX-015). *Nat Med* **6**: 1128–1133.

Ruffie P, Feld R, Minkin S, Cormier Y, Boutan-Laroze A, Ginsberg R *et al.* (1989). Diffuse malignant mesothelioma of the pleura in Ontario and Quebec: a retrospective study of 332 patients. *J Clin Oncol* **7**: 1157–1168.

Rusch VW, Piantadosi S, Holmes EC. (1991). The role of extrapleural pneumonectomy in malignant pleural mesothelioma. A Lung Cancer Study Group trial. *J Thorac Cardiovasc Surg* **102**: 1–9.

Ryan CW, Herndon J, Vogelzang NJ. (1998). A review of chemotherapy trials for malignant mesothelioma. *Chest* **113**: 66S–73S.

Sterman DH, Recio A, Carroll RG, Gillespie CT, Haas A, Vachani A *et al.* (2007). A phase I clinical trial of single-dose intrapleural IFN-beta gene transfer for malignant pleural mesothelioma and metastatic pleural effusions: high rate of antitumor immune responses. *Clin Cancer Res* **13**: 4456–4466.

Sterman DH, Recio A, Vachani A, Sun J, Cheung L, DeLong P *et al.* (2005). Long-term follow-up of patients with malignant pleural mesothelioma receiving high-dose adenovirus herpes simplex thymidine kinase/ganciclovir suicide gene therapy. *Clin Cancer Res* **11**: 7444–7453.

Sterman DH, Treat J, Litzky LA, Amin KM, Coonrod L, Molnar-Kimber K *et al.* (1998). Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: results of a phase I clinical trial in malignant mesothelioma. *Hum Gene Ther* **9**: 1083–1092.

Taki M, Kagawa S, Nishizaki M, Mizuguchi H, Hayakawa T, Kyo S *et al.* (2005). Enhanced oncolysis by a tropism-modified telomerase-specific replication-selective adenoviral agent OBP-405 ('Telomelysin-RGD'). *Oncogene* **24**: 3130–3140.

Tango Y, Taki M, Shirakiya Y, Ohtani S, Tokunaga N, Tsunemitsu Y *et al.* (2004). Late resistance to adenoviral p53-mediated apoptosis caused by decreased expression of Coxsackie-adenovirus receptors in human lung cancer cells. *Cancer Sci* **95**: 459–463.

Umeoka T, Kawashima T, Kagawa S, Teraishi F, Taki M, Nishizaki M *et al.* (2004). Visualization of intrathoracically disseminated solid tumors in mice with optical imaging by telomerase-specific amplification of a transferred green fluorescent protein gene. *Cancer Res* **64**: 6259–6265.

Uno F, Fujiwara T, Takata Y, Ohtani S, Katsuda K, Takaoka M *et al.* (2001). Antisense-mediated suppression of human heparanase gene expression inhibits pleural dissemination of human cancer cells. *Cancer Res* **61**: 7855–7860.

Yang CT, You L, Uematsu K, Yeh CC, McCormick F, Jablons DM. (2001). p14(ARF) modulates the cytolytic effect of ONYX-015 in mesothelioma cells with wild-type p53. *Cancer Res* **61**: 5959–5963.

Yang CT, You L, Yeh CC, Chang JW, Zhang F, McCormick F *et al.* (2000). Adenovirus-mediated p14(ARF) gene transfer in human mesothelioma cells. *J Natl Cancer Inst* **92**: 636–641.

Supplementary Information accompanies the paper on the Oncogene website (http://www.nature.com/onc)

In Vivo Biological Purging for Lymph Node Metastasis of Human Colorectal Cancer by Telomerase-Specific Oncolytic Virotherapy

Toru Kojima, MD, Yuichi Watanabe, PhD,†‡ Yuuri Hashimoto, BS,†‡ Shinji Kuroda, MD,* Yasumoto Yamasaki, MD,* Shuya Yano, MD,* Masaaki Ouchi, BS,‡ Hiroshi Tazawa, MD, PhD,† Futoshi Uno, MD, PhD,*† Shunsuke Kagawa, MD, PhD,*† Satoru Kyo, MD, PhD,§ Hiroyuki Mizuguchi, PhD,¶ Yasuo Urata, BS,‡ Noriaki Tanaka, MD, PhD,* and Toshiyoshi Fujiwara, MD, PhD*†*

Background/Objective: The aim of this study was to develop a less invasive way of targeting lymph node metastasis for the treatment of human gastrointestinal cancer. Lymphatic invasion is a major route for cancer cell dissemination, and adequate treatment of locoregional lymph nodes is required for curative treatment in patients with malignancies.

Methods: Human telomerase reverse transcription (hTERT) is the catalytic subunit of telomerase, which is highly active in cancer cells but quiescent in most normal somatic cells. OBP-301 (Telomelysin) is an attenuated adenovirus with oncolytic potency that contains the hTERT promoter element to regulate viral replication. We examined whether OBP-301 injected into the primary tumor might be useful for purging micrometastasis from regional lymph nodes in an orthotopic colorectal cancer model.

Results: OBP-301 was intratumorally injected into HT29 tumors orthotopically implanted into the rectum in BALB/c *nu/nu* mice. By using a highly sensitive quantitative PCR analysis that targets the human-specific *Alu* sequence, we showed that OBP-301 caused viral spread into the regional lymphatic area and selectively replicated in neoplastic lesions, resulting in tumor-cell-specific death in metastatic lymph nodes. Moreover, although the surgical removal of primary tumors increased the tendency of lymph node metastasis, preoperative intratumoral injection of virus significantly reduced lymph node metastasis.

Conclusions: Our results indicate that intratumoral injection of OBP-301 mediates effective in vivo purging of metastatic tumor cells from regional lymph nodes, which may help optimize treatment of human cancer, especially gastrointestinal malignancies.

(*Ann Surg* 2010;251: 1079–1086)

From the *Division of Surgical Oncology, Department of Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan; †Center for Gene and Cell Therapy, Okayama University Hospital, Okayama, Japan; ‡Oncolys BioPharma, Inc., Tokyo, Japan; §Department of Obstetrics and Gynecology, Kanazawa University School of Medicine, Kanazawa, Japan; and ¶Department of Biochemistry and Molecular Biology, Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan.

Supported in part by grants from the Ministry of Education, Science, and Culture, Japan (to T. F.); grants from the Ministry of Health and Welfare, Japan (to T. F.).

Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Web site (www.annalsofsurgery.com).

Reprints: Toshiyoshi Fujiwara, MD, PhD, Center for Gene and Cell Therapy, Okayama University Hospital, 2–5-1 Shikata-cho, Okayama 700–8558, Japan. E-mail: toshi_f@md.okayama-u.ac.jp.

ISSN: 0003-4932/10/25106-1079
DOI: 10.1097/SLA.0b013e3181deb69d

Lymph node status provides important information for both the diagnosis and treatment of human cancer. Lymphatic invasion is a major route for cancer cell dissemination, and lymph node metastasis is a frequent type of recurrence that is associated with a survival disadvantage in many types of cancers.[1–3] Therefore, adequate resection of the locoregional lymph nodes is required for curative treatment in patients with malignancies.[4,5] Extended lymphadenectomy, however, may greatly impair quality of life, especially for patients with early stage epithelial neoplasms in the gastrointestinal tract.[6] Their primary tumors can be removed by new endoluminal therapeutic techniques such as endoscopic submucosal dissection; however, patients with submucosal invasion, lymphovascular infiltration of cancer cells, or undifferentiated histology often become candidates for surgical organ resection with lymphadenectomy, because there is a risk of regional lymph node metastasis, although the frequency is relatively low.[7] Thus, a less invasive way to selectively treat lymph node metastasis would benefit these patients by allowing them to avoid a prophylactic surgery.

Oncolytic viruses that can selectively replicate in tumor cells and lyse infected cells have been extensively investigated as novel anticancer agents.[8–10] These vectors are designed to induce virus-mediated lysis of tumor cells after selective viral propagation within the tumor cell. We previously developed an attenuated adenovirus designated OBP-301 (Telomelysin) that drives the *E1A* and *E1B* genes under the human telomerase reverse transcription (hTERT) promoter.[10–13] The clinical development of OBP-301 as a monotherapy for various solid tumors is currently underway in the United States.[14] We and others have reported that human adenovirus is capable of effective transport into the lymphatic circulation.[15–17] Injection of OBP-401 (TelomeScan), telomerase-specific, replication-competent adenovirus expressing green fluorescent protein (GFP) into primary tumors allows its lymphatic spread, which in turn induces viral replication in metastatic lymph nodes, allowing us to directly image the micrometastases.

In the present study, we explore whether viruses injected into the established primary tumors could traffic to regional lymph nodes and selectively kill metastatic tumor cells in a human colorectal tumor xenograft model. To measure virus-mediated therapeutic efficacy against lymphatic micrometastasis, we established a highly sensitive real-time PCR method targeting human *Alu* sequences.

MATERIALS AND METHODS

Cell Line and Viruses

The human colorectal cancer cell line HT29 was routinely propagated in monolayer culture in McCoy's medium. The recombinant replication-selective, tumor-specific adenovirus vector OBP-301 (Telomelysin), in which the hTERT promoter element drives the expression of *E1A* and *E1B* genes linked with an internal ribosome entry site, was previously constructed and



FIGURE 1. In vitro purging effect of OBP-301 infection on HT29 human colorectal cancer cells. We plated 5×10^6 PBMC or mouse splenocytes per well along with 2×10^5 HT29 human colorectal cancer cells. After 24 hours, the mixed culture was infected with 2×10^7 PFU of OBP-301 or dl312 (100 multiplicity of infection [MOI] for HT29 cells) for 96 hours, followed by infection with OBP-401 at 2×10^6 PFU (10 MOI for HT29 cells) to visualize viable HT29 cells (see Figure, Supplemental Digital Content 2, available at: http://links.lww.com/SLA/A39, which illustrates the procedures for in vitro purging experiments). A, The number of GFP-positive, viable HT29 cells was counted in 3 random fields at a magnification of × 200 under the fluorescent microscope. Values represent means ± SEM, and a single asterisk indicates $P < 0.05$ as compared with the other groups. B, The intensity of GFP fluorescence in each treatment group was also measured by using a fluorescence microplate reader. Values are relative to mock (mock = 1) and represent means ± SEM. A single asterisk indicates $P < 0.05$. C, Toxicity of OBP-301 infection was assessed for human lymphocytes. A total of 5×10^6 PBMCs were exposed to 2×10^7 PFU of OBP-301 or dl312 for 96 hours, and their viability was then determined by trypan blue exclusion. D, An efficient purging effect of OBP-301 on HT29 cells in mouse splenocytes. To mimic the animal experiments in vitro, HT29 cells mixed with splenocytes from BALB/c *nu/nu* mice were exposed to OBP-301 or dl312 for 96 hours, followed by OBP-401 infection. The number of cells positive for GFP was counted as described above, and presented as the mean ± SEM. A single asterisk indicates $P < 0.05$.

characterized.[11] OBP-401 (TelomeScan) is a telomerase-specific, replication-competent adenovirus variant in which the replication cassette and *GFP* gene under the control of the cytomegalovirus promoter were inserted into the E3 region for monitoring viral replication[15] (see Figure, Supplemental Digital Content 1, online only, available at http://links.lww.com/SLA/A38, which illustrates schematic DNA structures of telomerase-specific viruses). The *E1A*-deleted adenovirus vector lacking a cDNA insert (dl312) was also used as a control vector.

In Vitro Purging Experiments

For in vitro purging studies, peripheral blood samples were drawn from healthy volunteers, and mononuclear cells were isolated by sedimentation over Ficoll-Hypaque. Mouse spleens were removed aseptically and gently crushed with the flat end of a sterile syringe. The cells were passed through nylon mesh and then placed in buffered ammonium chloride solution to produce osmotic lysis of erythrocytes. We plated peripheral blood mononuclear cells (PBMC) or mouse splenocytes per well along with HT29 cells. The purging effect was assessed with an Eclipse TS-100 fluorescent microscope (Nikon, Tokyo, Japan) by counting the number of GFP-positive cells 24 hours after OBP-401 infection (see Figure, Supplemental Digital Content 2, online only, available at http://links.lww.com/SLA/A39, which illustrates the procedures for in vitro purging experiments). GFP fluorescence was also measured by using a fluorescence microplate reader (DS Pharma Biomedical, Osaka, Japan) with excitation/emission at 485 nm/528 nm.

Xenograft Model of Lymph Node Metastasis

The experimental protocol was approved by the Ethics Review Committee for Animal Experimentation of our institution. The implantation procedures for human rectal cancer xenografts were described previously.[15] Cell suspensions of HT29 cells at a density of 5×10^6 cells in 100 μL of Matrigel (BD Biosciences, Bedford, MA) were slowly injected into the submucosal layer of the rectum by using a 27-gauge needle. For pathologic evaluation of lymph node metastasis, mice were killed and all para-aortic or iliac lymph nodes were isolated and stained with hematoxylin and eosin.

In Vivo Fluorescence Imaging

In vivo GFP fluorescence imaging was acquired by illuminating the animal with a Xenon 150 W lamp. The re-emitted fluorescence was collected through a long pass filter on a Hamamatsu C5810 3-chip color cooled charged-coupled device (CCD) camera (Hamamatsu Photonics Systems, Hamamatsu, Japan). Abdominal images were also obtained during laparotomy with the IVIS CCD camera and analyzed with Living Image 2.20.1 software (Xenogen/Caliper Life Sciences, Hopkinton, MA) for the quantification of lymph node metastasis.

Quantitative Real-Time PCR Analysis

To measure the amounts of human tumor cells in mouse lymph nodes, we applied a previously described quantitative PCR assay that uses primer sets to amplify human *Alu* sequences present in mouse lymph node DNA extracts. Genomic DNA was extracted